Biopharma & Life Sciences

Sana Biotechnology Executive Compensation (FY25)

Name: Sana Biotechnology (SANA) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

SANA · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Steven Harr

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The paid brief on Sana Biotechnology

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 5, 2026Latest filing (DEF 14A): April 24, 2026

4 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Sana Biotechnology brief$500Get the executive brief

Velarion Intel, one year, every company

128 figures on this page, cited to the filing that reported them. See the citations

This company is not required to report a chief executive pay ratio.

Frequently asked questions

Answers drawn from the data on this page.

Who is Sana Biotechnology's chief executive and what were they paid?

Steven Harr, President, Chief Executive Officer, and Director, received $2,903,010 in total compensation for fiscal 2025. Harr's total was 67.0% lower than the $8,788,580 reported for fiscal 2024.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Steven Harr President, Chief Executive Officer, and Director	◇	—	—	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Douglas Williams Former Executive Vice President and President, Research and Development	◇	—	◇	◇	◇	—	◇	◇
Steven Harr President, Chief Executive Officer, and Director	◇	—	—	◇	◇	—	◇	◇
Nathan Hardy Former Executive Vice President, Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Bernard Cassidy Executive Vice President, General Counsel, and Corporate Secretary	◇	—	—	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Steven Harr President, Chief Executive Officer, and Director	◇	—	◇	◇	◇	—	◇	◇
Nathan Hardy Former Executive Vice President, Chief Financial Officer Departed during or after this year	◇	—	◇	◇	—	—	◇	◇
Douglas Williams Former Executive Vice President and President, Research and Development Departed during or after this year	◇	—	◇	◇	—	—	◇	◇
Bernard Cassidy Executive Vice President, General Counsel, and Corporate Secretary	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Steven Harr President, Chief Executive Officer, and Director	◇	—	◇	◇	◇	—	◇	◇
Bernard Cassidy Former Executive Vice President, General Counsel, and Corporate Secretary Departed during or after this year	◇	—	◇	◇	—	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Bernard Cassidy	OPTION	—	—	—	—	—	—	◇
Bernard Cassidy	RSU	—	—	—	—	—	—	◇
Steven Harr	OPTION	—	—	—	—	—	—	◇
Steven Harr	RSU	—	—	—	—	—	—	◇

Fiscal 2023, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Steven Harr	Option	◇	—	◇	3/5/2035
	Option	◇	—	◇	3/6/2034
	Option	◇	—	◇	3/1/2033
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/2/2032
Bernard Cassidy	Option	◇	—	◇	3/5/2035
	Option	◇	—	◇	9/14/2032
	Option	◇	—	◇	3/6/2034
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/1/2033
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Bernard Cassidy

Former Executive Vice President, General Counsel, and Corporate Secretary

Non-solicit period

◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Robert L. Rosiello	◇	—	◇	—	—	—	◇
Hans E. Bishop Board chair	◇	—	◇	—	—	—	◇
Michelle Seitz, CFA	◇	—	◇	—	—	—	◇
Alise S. Reicin, M.D	◇	—	◇	—	—	—	◇
Joshua H. Bilenker, M.D	◇	—	◇	—	—	—	◇
Patrick Y. Yang, Ph.D	◇	—	◇	—	—	—	◇
Richard Mulligan, Ph.D	◇	—	◇	—	—	—	◇
Robert Nelsen	◇	—	◇	—	—	—	◇
Mary Agnes (Maggie) Wilderotter	◇	—	◇	—	—	—	◇
Douglas Cole, M.D	◇	—	—	—	—	—	◇

Steven D. Harr, M.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Steven Harr (President, Chief Executive Officer, and Director), FY2025 total compensation $2,903,010 (base salary $696,140) [exec_comp, SEC accession 0001193125-26-174883, filed 2026-04-24]

See a complete sample report

What this page does not include

Everything above is a fact Sana Biotechnology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

128 figures on this page, cited to the filing that reported them.

128 cited to the filing

Documents cited

DEF 14A, filed April 24, 2026
0001193125-26-174883
DIRECTOR COMPENSATION · Director Compensation · EXECUTIVE COMPENSATION · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
EX-10, filed March 3, 2026
0001193125-26-088215
Exhibit
DEF 14A, filed April 25, 2025
0001193125-25-094656
Summary Compensation Table
DEF 14A, filed April 26, 2024
0001193125-24-115454
Summary Compensation Table

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Sana Biotechnology executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SANA (accessed 2026).

Short form: data: Velarion

The paid brief for Sana Biotechnology

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

4 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/SANA/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Sana Biotechnology executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Sana Biotechnology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Sana Biotechnology

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

What this page does not include

Citations

Documents cited

The paid brief for Sana Biotechnology

Biopharma & Life Sciences rankings

Terms on this page